Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965159 | 0.77 | SYK (0.47) | BDKRB2KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6643616 | 0.77 | KDM4E (0.52) | KDM4EMAPTSMN1; SMN2OPRK1MEN1 | |
| SCHEMBL660406 | 0.77 | KDM4E (0.43) | BDKRB2KDM4EMAPTSMN1; SMN2MEN1 | |
| SCHEMBL1564088 | 0.75 | BDKRB2 (0.55) | BDKRB2KDM4EMAPT | |
| SCHEMBL6639297 | 0.75 | KDM4E (0.50) | KDM4EMAPTSMN1; SMN2OPRK1MEN1 | |
| SCHEMBL660152 | 0.74 | KDM4E (0.44) | KDM4EMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6643288 | 0.74 | KDM4E (0.49) | KDM4EMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7748595 | 0.73 | ABCB1 (0.44) | KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6643141 | 0.73 | KDM4E (0.48) | KDM4EMAPTSMN1; SMN2OPRK1MEN1 | |
| SCHEMBL659122 | 0.73 | KDM4E (0.76) | KDM4EMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012024419-A2 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | BDKRB2 1/4885KDM4E 3092/4885GABRA1 194/4885 |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | BDKRB2 1/4885KDM4E 3092/4885GABRA1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.